Page 12 - JCTR-10-6

322 Hanno et al.ǀ Journal of Clinical and Translational Research 2024; 10(6): 317-324
1975 Declaration of Helsinki. The trial was retrospectively of acid suppression are related to Helicobacter
registered on October 20, 2022; the trial registration serial pylori eradication by triple therapy. Helicobacter
number is 0305757, and the reference number is FWA NO: 2007;12:317-23.
00018699. Each participant’s consent was acquired in advance. doi: 10.1111/j.1523-5378.2007.00508.x
Patients provided written informed consent before participating [9] Graham DY, Fischbach L. Helicobacter pylori treatment
in this research. in the era of increasing antibiotic resistance. Gut
Consent for Publication 2010;59(8):1143-53.
doi: 10.1136/gut.2009.192757
Patients who took part in this study agreed to publish their data. [10] Smith SM, O’Morain C, McNamara D. Antimicrobial
Availability of Data susceptibility testing for Helicobacter pylori in times of
increasing antibiotic resistance. World J Gastroenterol
The materials supporting the study’s results are 2014;20:9912-21.
included in the article. Additional information is doi: 10.3748/wjg.v20.i29.9912
accessible through the following link: https://drive. [11] Alboraie M, Elhossary W, Aly OA, Abbas B,
google.com/drive/folders/1m9wImunKzTJIV5H8zx1D3-_ Abdelsalam L, Ghaith D, et al. Egyptian recommendations
PYh1KsJ4L?usp=sharing for management of Helicobacter pylori infection: 2018
References report. Arab J Gastroenterol 2019;20:175-9.
doi: 10.1016/j.ajg.2019.09.001
[1] Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS,
et al. Diagnosis of Helicobacter pylori infection: Current [12] Metwally M, Ragab R, Abdel Hamid HS, Emara N,
Elkholy H. Helicobacterpylori antibiotic resistance
options and developments. World J Gastroenterol in Egypt: A single-center study. Infect Drug Resist
2015;21:11221-35. 2022;15:5905-13.
doi: 10.3748/wjg.v21.i40.11221 doi: 10.2147/IDR.S386082
[2] Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, [13] Murakami K, Furuta T, Ando T, Nakajima T, Inui Y,
Liou JM, Schulz C, et al. Management of Helicobacter Oshima T, et al. Multi-center randomized controlled
pylori infection: The maastricht VI/florence consensus study to establish the standard third-line regimen for
report. Gut 2022;71:1724-62. Helicobacter pylori eradication in Japan. J Gastroenterol
doi: 10.1136/gutjnl-2022-327745 2013;48:1128-35.
[3] Nordestgaard MA, Spiegelhauer RM, Frandsen HT, doi: 10.1007/s00535-012-0731-8
Gren C, Stauning AT, Andersen PL. Clinical manifestations [14] Shin JM, Inatomi N, Munson K, Strugatsky D,
of the Epsilonproteobacteria (Helicobacter pylori). Tokhtaeva E, Vagin O, et al. Characterization of a
In: Roesler BM, editor. Helicobacter Pylori. London: novel potassium-competitive acid blocker of the
IntechOpen; 2018. p. 21-32. gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-
doi: 10.5772/intechopen.80331 3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine
[4] Liou JM, Malfertheiner P, Lee Y, Sheu B, Sugano K, monofumarate (TAK-438). J Pharmacol Exp Ther
Cheng H, et al. Screening and eradication of Helicobacter 2011;339:412-20.
pylori for gastric cancer prevention: The Taipei global doi: 10.1124/jpet.111.185314
consensus. Gut 2020;69:2093-112. [15] Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H,
doi: 10.1136/gutjnl-2020-322368 Arikawa Y, et al. 1-[5-(2-fluorophenyl)-1-(pyridin-3-
[5] Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine
clinical guideline: Treatment of Helicobacter pylori monofumarate (TAK-438), a novel and potent potassium-
infection. Am J Gastroenterol 2017;112(2):212-39. competitive acid blocker for the treatment of acid-related
doi: 10.1038/ajg.2016.563 diseases. J Pharmacol Exp Ther 2010;335:231-8.
[6] Malfertheiner P, Megraud F, O’Morain CA, Atherton J, doi: 10.1124/jpet.110.170274
Axon AT, Bazzoli F, et al. Management of Helicobacter [16] Scott D, Weeks D, Melchers K, Sachs G. The life
pylori infection--the maastricht IV/ florence consensus and death of Helicobacter pylori. Gut 1998;43 Suppl
report. Gut 2012;61:646-64. 1:S56-60.
doi: 10.1136/gutjnl-2012-302084 doi: 10.1136/gut.43.2008.s56
[7] Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. [17] Hunt RH, Scarpignato C. Potassium-competitive acid
Acid, protons and Helicobacter pylori. Yale J Biol Med blockers (P-CABs): Are they finally ready for prime
1996;69:301-16. time in acid-related disease? Clin Transl Gastroenterol
[8] Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, 2015;6:e119.
Ikuma M, et al. Evidence that the degree and duration doi: 10.1038/ctg.2015.39

DOI: http://doi.org/10.36922/jctr.24.00043